{"nctId":"NCT00321464","briefTitle":"A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.","startDateStruct":{"date":"2006-04-01","type":"ACTUAL"},"conditions":["Bone Metastases"],"count":2049,"armGroups":[{"label":"zoledronic acid","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Zoledronic Acid"]},{"label":"denosumab","type":"EXPERIMENTAL","interventionNames":["Biological: Denosumab"]}],"interventions":[{"name":"Denosumab","otherNames":[]},{"name":"Zoledronic Acid","otherNames":["Zometa"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adults with histologically or cytologically confirmed breast adenocarcinoma\n* radiographic evidence of at least one bone mets\n* Easter Cooperative Oncology Group status of 0, 1 or 2;\n* adequate organ function\n\nExclusion Criteria:\n\n* Current or prior IV bisphosphonate administration\n* current or prior oral bisphosphonates for bone mets\n* life expectancy of less than 6 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to First On-Study Skeletal Related Event (SRE) (Non-inferiority)","description":"Time to first on-study skeletal-related event (SRE) using a non-inferiority analysis. The median time to first skeletal-related event could not be estimated in one treatment arm, so the subject incidence is presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"372","spread":null},{"groupId":"OG001","value":"315","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First On-Study Skeletal-Related Event (Superiority)","description":"Time to first on-study skeletal-related event (SRE) using a superiority analysis. The median time to first skeletal-related event could not be estimated in one treatment arm, so the subject incidence is presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"372","spread":null},{"groupId":"OG001","value":"315","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First and Subsequent On-Study Skeletal-Related Event","description":"Time to first and subsequent on-study skeletal-related event (SRE) using a multiple event analysis. To be considered a subsequent SRE, the event must occur at least 21 days after the previous SRE. This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative number of events.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"608","spread":null},{"groupId":"OG001","value":"474","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":471,"n":1013},"commonTop":["Nausea","Fatigue","Arthralgia","Back pain","Vomiting"]}}}